Chemical formula: C₁₅H₂₁N₃O₂ Molecular mass: 275.346 g/mol PubChem compound: 5983
There is no experience of the use of physostigmine in pregnant women. Physostigmine passes to the placenta. Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, birth and postnatal development. The potential risk for humans is unknown. Physostigmine should only be used during pregnancy if considered to be strictly necessary by the treating doctor.
There is no experience of the use of physostigmine during breastfeeding. It is unknown whether physostigmine, the active substance contained in physostigmine, is excreted in human breast milk. Physostigmine should only be used during breastfeeding if considered to be strictly necessary by the treating doctor.
None known.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
